Read More Pharma Industry News FDA approves Neurocrine Biosciences’ Ingrezza for tardive dyskinesia Neurocrine Biosciences has achieved a major milestone with the U.S. Food and Drug Administration (FDA) approving its medication,… bypharmanewsdailyApril 15, 2017
